370 related articles for article (PubMed ID: 17897678)
1. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
De Stefano N; Filippi M; Hawkins C;
J Neurol Sci; 2008 Mar; 266(1-2):44-50. PubMed ID: 17897678
[TBL] [Abstract][Full Text] [Related]
2. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Vollmer T; Panitch H; Bar-Or A; Dunn J; Freedman MS; Gazda SK; Campagnolo D; Deutsch F; Arnold DL
Mult Scler; 2008 Jun; 14(5):663-70. PubMed ID: 18424479
[TBL] [Abstract][Full Text] [Related]
3. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G; Filippi M; Wolinsky JS
Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
[TBL] [Abstract][Full Text] [Related]
4. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
[TBL] [Abstract][Full Text] [Related]
5. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
6. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
[TBL] [Abstract][Full Text] [Related]
7. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
Cohen JA; Calabresi PA; Chakraborty S; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Imrey PB; Ivancic DM; Mandell BF; Perryman JE; Scott TF; Skaramagas TT; Zhang H;
Mult Scler; 2008 Apr; 14(3):370-82. PubMed ID: 18208877
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
Cohen JA; Rovaris M; Goodman AD; Ladkani D; Wynn D; Filippi M;
Neurology; 2007 Mar; 68(12):939-44. PubMed ID: 17372130
[TBL] [Abstract][Full Text] [Related]
9. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Metz LM; Li D; Traboulsee A; Myles ML; Duquette P; Godin J; Constantin M; Yong VW;
Mult Scler; 2009 Oct; 15(10):1183-94. PubMed ID: 19776092
[TBL] [Abstract][Full Text] [Related]
10. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
Zivadinov R; Zorzon M; De Masi R; Nasuelli D; Cazzato G
J Neurol Sci; 2008 Apr; 267(1-2):28-35. PubMed ID: 17945260
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
12. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis.
Miller A; Spada V; Beerkircher D; Kreitman RR
Mult Scler; 2008 May; 14(4):494-9. PubMed ID: 18208875
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial.
Rovaris M; Comi G; Rocca MA; Valsasina P; Ladkani D; Pieri E; Weiss S; Shifroni G; Wolinsky JS; Filippi M;
Mult Scler; 2007 May; 13(4):502-8. PubMed ID: 17483532
[TBL] [Abstract][Full Text] [Related]
14. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
16. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
[TBL] [Abstract][Full Text] [Related]
17. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis.
Zivadinov R; Bagnato F; Nasuelli D; Bastianello S; Bratina A; Locatelli L; Watts K; Finamore L; Grop A; Dwyer M; Catalan M; Clemenzi A; Millefiorini E; Bakshi R; Zorzon M
J Neurol Sci; 2004 Aug; 223(2):185-93. PubMed ID: 15337621
[TBL] [Abstract][Full Text] [Related]
18. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
Zhao Y; Traboulsee A; Petkau AJ; Li D
Neurology; 2008 Mar; 70(13 Pt 2):1092-7. PubMed ID: 18003938
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
Massacesi L; Parigi A; Barilaro A; Repice AM; Pellicanò G; Konze A; Siracusa G; Taiuti R; Amaducci L
Arch Neurol; 2005 Dec; 62(12):1843-7. PubMed ID: 16344342
[TBL] [Abstract][Full Text] [Related]
20. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
Arnold DL; Campagnolo D; Panitch H; Bar-Or A; Dunn J; Freedman MS; Gazda SK; Vollmer T
J Neurol; 2008 Oct; 255(10):1473-8. PubMed ID: 18854910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
